Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial

摘要

Background Few treatment options exist for second-line treatment of malignant pleural mesothelioma. We aimed to assess the antibody-drug conjugate anetumab ravtansine versus vinorelbine in patients with unresectable locally advanced or metastatic disease overexpressing mesothelin who had progressed on first-line platinum-pemetrexed chemotherapy with or without bevacizumab. Methods In this phase 2, randomised, open-label study, done at 76 hospitals in 14 countries, we enrolled adults (aged >= 18 years) with unresectable locally advanced or metastatic malignant pleural mesothelioma, an Eastern Cooperative Oncology Group performance status of 0-1, and who had progressed on first-line platinum-pemetrexed chemotherapy with or without bevacizumab. Participants were prospectively screened for mesothelin overexpression (defined as 2+ or 3+ mesothelin membrane staining intensity on at least 30 of viable tumour cells by immunohistochemistry) and were randomly assigned (2:1), using an interactive voice and web response system provided by the sponsor, to receive intravenous anetumab ravtansine (6.5 mg/kg on day 1 of each 21-day cycle) or intravenous vinorelbine (30 mg/m(2) once every week) until progression, toxicity, or death. The primary endpoint was progression-free survival according to blinded central radiology review, assessed in the intention-to-treat population, with safety assessed in all participants who received any study treatment. This study is registered with ClinicalTrials.gov, NCT02610140, and is now completed. Findings Between Dec 3, 2015, and May 31, 2017, 589 patients were enrolled and 248 mesothelin-overexpressing patients were randomly allocated to the two treatment groups (166 patients were randomly assigned to receive anetumab ravtansine and 82 patients were randomly assigned to receive vinorelbine). 105 (63) of 166 patients treated with anetumab ravtansine (median follow-up 4.0 months IQR 1.4-5.5) versus 43 (52) of 82 patients treated with vinorelbine (3.9 months 1.4-5.4) had disease progression or died (median progression-free survival 4.3 months 95 CI 4.1-5.2 vs 4.5 months 4.1-5.8; hazard ratio 1.22 0.85-1.74; log-rank p=0.86). The most common grade 3 or worse adverse events were neutropenia (one 1 of 163 patients for anetumab ravtansine vs 28 39 of 72 patients for vinorelbine), pneumonia (seven 4 vs five 7), neutrophil count decrease (two 1 vs 12 17), and dyspnoea (nine 6 vs three 4). Serious drug-related treatment-emergent adverse events occurred in 12 (7) patients treated with anetumab ravtansine and 11 (15) patients treated with vinorelbine. Ten (6) treatment-emergent deaths occurred with anetumab ravtansine: pneumonia (three 2), dyspnoea (two 1), sepsis (two 1), atrial fibrillation (one 1), physical deterioration (one 1), hepatic failure (one 1), mesothelioma (one 1), and renal failure (one 1; one patient had 3 events). One (1) treatment-emergent death occurred in the vinorelbine group (pneumonia). Interpretation Anetumab ravtansine showed a manageable safety profile and was not superior to vinorelbine. Further studies are needed to define active treatments in relapsed mesothelin-expressing malignant pleural mesothelioma. Copyright (C) 2022 Elsevier Ltd. All rights reserved.